title: Comparison of single injection of intravitreal triamcinolone versus single injection of intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusions with regard to changes in best corrected visual acuity and central macular thickness in the short term.
authors.forename: Aditya S
authors.initials: AS
authors.lastname: Kelkar
authors.forename: Mehmood G
authors.initials: MG
authors.lastname: Sayyad
authors.forename: Jai A
authors.initials: JA
authors.lastname: Kelkar
authors.forename: Shreekant B
authors.initials: SB
authors.lastname: Kelkar
authors.forename: Reena
authors.initials: R
authors.lastname: Narvankar
authors.forename: Aarofil
authors.initials: A
authors.lastname: Shaikh
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007267:Injections; D008266:Macula Lutea / Q000473:pathology*; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000503:physiopathology; D012189:Retrospective Studies; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide